Clinical Trial

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-31
notable Primary completion moved earlier: 2026-04-13 -> 2026-02-26 2026-07-31
minor Completion moved earlier: 2026-04-13 -> 2026-02-26 2026-07-31
Trial Details
NCT Number NCT06573281
Lead Sponsor GlaxoSmithKline
Conditions Respiratory Syncytial Virus Infections
Enrollment 213 participants
Start Date 2024-09-30
Primary Completion 2026-02-26 (estimated)
Study Completion 2026-02-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-30